Stocks Health care AKTS
NASDAQ · Health careAktis Oncology, Inc. (AKTS)
At June 30, 2026 it held $82.5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
What Aktis Oncology, Inc. does
Aktis Oncology, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker AKTS.
Latest SEC filings
What Aktis Oncology, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 13, 2026Quarterly report 10-Q · period to June 30, 2026
- August 13, 2026
- May 14, 2026Passive stake (5% or more) SCHEDULE 13G
- May 11, 2026Quarterly report 10-Q · period to March 31, 2026
- May 11, 2026
- April 16, 2026
- March 30, 2026
- March 30, 2026Annual report 10-K · period to December 31, 2025
- January 20, 2026Activist stake (5% or more) SCHEDULE 13D
- January 20, 2026Activist stake (5% or more) SCHEDULE 13D
Questions about AKTS
What does Aktis Oncology, Inc. do?
Aktis Oncology, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker AKTS.
When did Aktis Oncology, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 24, 2026.
Similar companies
Follow AKTS
Get an email when Aktis Oncology, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow AKTS: get an email when it filesWhere the numbers come from
Financial figures are the values Aktis Oncology, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.